Solicitation of Nominations for Appointment to the Tick-Borne Disease Working Group, 63124-63125 [2020-22062]
Download as PDF
<![CDATA[
63124
Federal Register / Vol. 85, No. 194 / Tuesday, October 6, 2020 / Notices
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: September 30, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–22018 Filed 10–5–20; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2020–22016 Filed 10–5–20; 8:45 am]
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4140–01–P
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
khammond on DSKJM1Z7X2PROD with NOTICES
Dated: September 30, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; PAR–20–072, NIAID
Investigator Initiated Program Project
Applications (P01 Clinical Trial Not
Allowed).
Date: November 4, 2020.
Time: 10:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F30A,
Rockville, MD 20892 (Telephone Conference
Call).
Contact Person: Ellen S. Buczko, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3F30A, Bethesda, MD
20892–9823, (240) 669–5028, ebuczko1@
niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
VerDate Sep<11>2014
17:52 Oct 05, 2020
Jkt 253001
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Clinical Trial
Implementation Cooperative Agreement
(U01), and NIAID SBIR Phase II Clinical Trial
Implementation Cooperative Agreement
(U44).
Date: October 28, 2020.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G33
Rockville, MD 20892 (Telephone Conference
Call).
Contact Person: Steven F. Santos, Ph.D.,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
Allergy and Infectious Diseases, National
Institutes of Health, 5601 Fishers Lane, Room
3G33, Rockville, MD 20892, 301–761–7049,
santossf@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: September 30, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–22019 Filed 10–5–20; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Emergency Awards: Rapid
Investigation of Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS–CoV–2) and
Coronavirus Disease 2019 (COVID–19).
Date: October 28–29, 2020.
Time: 9:30 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G22A,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Inka I. Sastalla, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G22A, Rockville, MD
20852, 301–761–6431, inka.sastalla@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: September 30, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–22017 Filed 10–5–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Solicitation of Nominations for
Appointment to the Tick-Borne
Disease Working Group
Office of Infectious Disease and
HIV/AIDS Policy (OIDP), Office of the
Assistant Secretary for Health (OASH),
Office of the Secretary, Department of
Health and Human Services.
AGENCY:
E:\FR\FM\06OCN1.SGM
06OCN1
Federal Register / Vol. 85, No. 194 / Tuesday, October 6, 2020 / Notices
ACTION:
Notice.
This notice will serve to
announce that the U.S. Department of
Health and Human Services (HHS) is
seeking nominations of non-federal
public (public) individuals who
represent diverse scientific disciplines
and views and are interested in being
considered for appointment to the TickBorne Disease Working Group
(TBDWG). Resumes or curricula vitae
from qualified individuals who wish to
be considered for appointment as a
member of the TBDWG are currently
being accepted.
DATES: Nominations must be received
no later than 5:00 p.m. ET, November 5,
2020.
ADDRESSES: All nominations should be
sent to the TBDWG email address at
tickbornedisease@hhs.gov. Please
indicate ‘‘TBDWG Nomination’’ in the
subject line of your email. The COVID–
19 pandemic has caused significant
disruption of mail addressed to the
TBDWG. As such, it is advised that all
nominations be submitted
electronically.
FOR FURTHER INFORMATION CONTACT:
James Berger, MS, MT (ASCP), SBB,
Senior Advisor for Blood and Tissue
Policy; Telephone: (202) 795–7608;
Email address: tickbornedisease@
hhs.gov. Website information about
activities of the TBDWG, as well as the
Charter, can be found at https://
www.hhs.gov/ash/advisory-committees/
tickbornedisease/.
SUPPLEMENTARY INFORMATION: Section
2062 of the 21st Century Cures Act,
Public Law 114–255, requires
establishment of the TBDWG. The
TBDWG is governed by provisions of
the Federal Advisory Committee Act,
Public Law 92–463, as amended (5
U.S.C. App.), which sets forth standards
for the formation and use of federal
advisory committees. The 21st Century
Cures Act is intended to advance the
research and development of new
therapies and diagnostics and make
substantial federal investments in a
wide range of health priorities. The
TBDWG is a non-discretionary federal
advisory committee.
Objectives and Scope of Activities.
The Secretary of HHS is responsible for
ensuring the conduct of and support for
epidemiological, basic, translational,
and clinical research related to vectorborne diseases, including tick-borne
diseases. The TBDWG was established
to help ensure interagency coordination
and to examine the prioritization of
such activities and research. The
TBDWG membership provides subject
matter expertise and reviews efforts
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:52 Oct 05, 2020
Jkt 253001
within the federal government related to
all tick-borne diseases. The TBDWG is
charged to provide a report to the HHS
Secretary and Congress biennially on its
findings, including advances made and
gaps in research, and to make
recommendations regarding appropriate
changes or improvements to such
activities and research.
Membership and Designation. The
TBDWG consists of 14 voting members
who represent diverse scientific
disciplines and views. The composition
includes seven public members and
seven federal members. Every effort is
made to ensure that the TBDWG is a
diverse group of individuals with
representation from various geographic
locations, racial and ethnic minorities,
genders, and persons living with
disabilities.
The public members consist of
representatives of the following
categories: (1) Physicians and other
medical providers with experience in
diagnosing and treating tick-borne
diseases; (2) scientists or researchers
with expertise; (3) patients and their
family members; and (4) nonprofit
organizations that advocate for patients
with respect to tick-borne disease. The
public members are classified as special
government employees. The public
members may be invited to serve
consecutive terms of up to four years
total. Terms of more than two years are
also contingent upon renewal of the
charter of the TBDWG. Any public
member who is appointed to fill the
vacancy of an unexpired term will be
appointed to serve for the remainder of
that term. A public member may serve
after the expiration of their term until
their successor has taken office, but no
longer than 180 days.
The federal members consist of one or
more representatives of each of the
following HHS agencies: OASH, the
Food and Drug Administration, the
Centers for Disease Control and
Prevention, and the National Institutes
of Health. Invitations of membership are
extended to other federal agencies and
offices as the HHS Secretary determines
appropriate and beneficial for
accomplishing the mission of the
TBDWG. Individuals who are appointed
to represent federal entities are
classified as regular government
employees. The federal members are
appointed to serve for the duration of
time that the TBDWG is authorized to
operate. Participation of the appointed
federal members is at the discretion of
their respective agency head.
Pursuant to advance written
agreement, public members of the
TBDWG will receive no stipend for the
advisory service that they render as
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
63125
members of the TBDWG. However,
public members will receive per diem
and reimbursement for travel expenses
incurred in relation to performing duties
for the TBDWG, as authorized by law
under 5 U.S.C. 5703 for persons who are
employed intermittently to perform
services for the federal government and
in accordance with federal travel
regulations.
Estimated Number and Frequency of
Meetings. The TBDWG will meet not
less than twice a year. The meetings will
be open to the public, except as
determined otherwise by the Secretary,
or another official to whom authority
has been delegated, in accordance with
the guidelines under Government in the
Sunshine Act, 5 U.S.C. 552b(c).
Nominations: Nominations of
individuals who have demonstrated
subject matter expertise will be
considered for appointment as public
voting members of the TBDWG. Selfnominations are acceptable. All
nominations should include the
following: (1) A letter of nomination
that clearly states the name and
affiliation of the nominee, the basis for
the nomination, and a statement from
the nominee that indicates that the
individual is willing to serve as a
member of the TBDWG, if selected; (2)
the name, address, telephone number,
and email address of the nominee; and
(3) a current copy of the nominee’s
curriculum vitae or resume, which must
be limited to 10 pages. Only the first 10
pages of resume or CV document will be
considered.
All public nominees will be subject to
federal ethics requirements for special
government employees. As required by
the Ethics Reform Act, Public Law 101–
194, special government employees
must receive annual ethics training and
submit a financial disclosure. An ethics
review must be conducted to ensure that
individuals appointed as public voting
members of the TBDWG are not
involved in any activity that may pose
a potential conflict of interest for the
official duties that are to be performed.
All federal members of the TBDWG will
be governed by the Standards of Ethical
Conduct for Employees of the Executive
Branch.
Dated: September 21, 2020.
James J. Berger,
Senior Advisor for Blood and Tissue Policy,
Designated Federal Officer, Tick-Borne
Disease Working Group.
[FR Doc. 2020–22062 Filed 10–5–20; 8:45 am]
BILLING CODE 4150–28–P
E:\FR\FM\06OCN1.SGM
06OCN1
]]>Agencies
[Federal Register Volume 85, Number 194 (Tuesday, October 6, 2020)]
[Notices]
[Pages 63124-63125]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-22062]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Solicitation of Nominations for Appointment to the Tick-Borne
Disease Working Group
AGENCY: Office of Infectious Disease and HIV/AIDS Policy (OIDP), Office
of the Assistant Secretary for Health (OASH), Office of the Secretary,
Department of Health and Human Services.
[[Page 63125]]
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice will serve to announce that the U.S. Department of
Health and Human Services (HHS) is seeking nominations of non-federal
public (public) individuals who represent diverse scientific
disciplines and views and are interested in being considered for
appointment to the Tick-Borne Disease Working Group (TBDWG). Resumes or
curricula vitae from qualified individuals who wish to be considered
for appointment as a member of the TBDWG are currently being accepted.
DATES: Nominations must be received no later than 5:00 p.m. ET,
November 5, 2020.
ADDRESSES: All nominations should be sent to the TBDWG email address at
[email protected]. Please indicate ``TBDWG Nomination'' in the
subject line of your email. The COVID-19 pandemic has caused
significant disruption of mail addressed to the TBDWG. As such, it is
advised that all nominations be submitted electronically.
FOR FURTHER INFORMATION CONTACT: James Berger, MS, MT (ASCP), SBB,
Senior Advisor for Blood and Tissue Policy; Telephone: (202) 795-7608;
Email address: [email protected]. Website information about
activities of the TBDWG, as well as the Charter, can be found at
https://www.hhs.gov/ash/advisory-committees/tickbornedisease/.
SUPPLEMENTARY INFORMATION: Section 2062 of the 21st Century Cures Act,
Public Law 114-255, requires establishment of the TBDWG. The TBDWG is
governed by provisions of the Federal Advisory Committee Act, Public
Law 92-463, as amended (5 U.S.C. App.), which sets forth standards for
the formation and use of federal advisory committees. The 21st Century
Cures Act is intended to advance the research and development of new
therapies and diagnostics and make substantial federal investments in a
wide range of health priorities. The TBDWG is a non-discretionary
federal advisory committee.
Objectives and Scope of Activities. The Secretary of HHS is
responsible for ensuring the conduct of and support for
epidemiological, basic, translational, and clinical research related to
vector-borne diseases, including tick-borne diseases. The TBDWG was
established to help ensure interagency coordination and to examine the
prioritization of such activities and research. The TBDWG membership
provides subject matter expertise and reviews efforts within the
federal government related to all tick-borne diseases. The TBDWG is
charged to provide a report to the HHS Secretary and Congress
biennially on its findings, including advances made and gaps in
research, and to make recommendations regarding appropriate changes or
improvements to such activities and research.
Membership and Designation. The TBDWG consists of 14 voting members
who represent diverse scientific disciplines and views. The composition
includes seven public members and seven federal members. Every effort
is made to ensure that the TBDWG is a diverse group of individuals with
representation from various geographic locations, racial and ethnic
minorities, genders, and persons living with disabilities.
The public members consist of representatives of the following
categories: (1) Physicians and other medical providers with experience
in diagnosing and treating tick-borne diseases; (2) scientists or
researchers with expertise; (3) patients and their family members; and
(4) nonprofit organizations that advocate for patients with respect to
tick-borne disease. The public members are classified as special
government employees. The public members may be invited to serve
consecutive terms of up to four years total. Terms of more than two
years are also contingent upon renewal of the charter of the TBDWG. Any
public member who is appointed to fill the vacancy of an unexpired term
will be appointed to serve for the remainder of that term. A public
member may serve after the expiration of their term until their
successor has taken office, but no longer than 180 days.
The federal members consist of one or more representatives of each
of the following HHS agencies: OASH, the Food and Drug Administration,
the Centers for Disease Control and Prevention, and the National
Institutes of Health. Invitations of membership are extended to other
federal agencies and offices as the HHS Secretary determines
appropriate and beneficial for accomplishing the mission of the TBDWG.
Individuals who are appointed to represent federal entities are
classified as regular government employees. The federal members are
appointed to serve for the duration of time that the TBDWG is
authorized to operate. Participation of the appointed federal members
is at the discretion of their respective agency head.
Pursuant to advance written agreement, public members of the TBDWG
will receive no stipend for the advisory service that they render as
members of the TBDWG. However, public members will receive per diem and
reimbursement for travel expenses incurred in relation to performing
duties for the TBDWG, as authorized by law under 5 U.S.C. 5703 for
persons who are employed intermittently to perform services for the
federal government and in accordance with federal travel regulations.
Estimated Number and Frequency of Meetings. The TBDWG will meet not
less than twice a year. The meetings will be open to the public, except
as determined otherwise by the Secretary, or another official to whom
authority has been delegated, in accordance with the guidelines under
Government in the Sunshine Act, 5 U.S.C. 552b(c).
Nominations: Nominations of individuals who have demonstrated
subject matter expertise will be considered for appointment as public
voting members of the TBDWG. Self-nominations are acceptable. All
nominations should include the following: (1) A letter of nomination
that clearly states the name and affiliation of the nominee, the basis
for the nomination, and a statement from the nominee that indicates
that the individual is willing to serve as a member of the TBDWG, if
selected; (2) the name, address, telephone number, and email address of
the nominee; and (3) a current copy of the nominee's curriculum vitae
or resume, which must be limited to 10 pages. Only the first 10 pages
of resume or CV document will be considered.
All public nominees will be subject to federal ethics requirements
for special government employees. As required by the Ethics Reform Act,
Public Law 101-194, special government employees must receive annual
ethics training and submit a financial disclosure. An ethics review
must be conducted to ensure that individuals appointed as public voting
members of the TBDWG are not involved in any activity that may pose a
potential conflict of interest for the official duties that are to be
performed. All federal members of the TBDWG will be governed by the
Standards of Ethical Conduct for Employees of the Executive Branch.
Dated: September 21, 2020.
James J. Berger,
Senior Advisor for Blood and Tissue Policy, Designated Federal Officer,
Tick-Borne Disease Working Group.
[FR Doc. 2020-22062 Filed 10-5-20; 8:45 am]
BILLING CODE 4150-28-P
